Cargando…
(411) Safety and Efficacy of Monoclonal Antibodies Against Sars-Cov-2 in a Heart Transplant Population
PURPOSE: The COVID-19 pandemic has been an unprecedented situation, possibly more so for immunocompromised individuals at higher risk for infection and serious complications. While vaccinations are available, immunocompromised patients are unlikely to mount a significant immune response. Monoclonal...
Autores principales: | Brink, H., Stoller, D., Lowes, B., Lundgren, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068083/ http://dx.doi.org/10.1016/j.healun.2023.02.426 |
Ejemplares similares
-
Pulmonary Function Testing Pre–heart Transplant Predicts Posttransplant Survival
por: Lundgren, Scott W., et al.
Publicado: (2021) -
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
por: Diamond, Michael, et al.
Publicado: (2021) -
Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022) -
Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants
por: Boonkrai, Chatikorn, et al.
Publicado: (2023) -
411. Comparison of clinical outcomes between early and delayed transplantation after SARS-CoV-2 infection
por: Reum Kim, A, et al.
Publicado: (2023)